The FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for the treatment of adults with ...
March 25 (Reuters) - Corcept Therapeutics shares jumped more than 32% to nearly a two-month high on Wednesday after the U.S.
FDA authorization covers platinum-resistant disease after 1–3 prior lines, with mandatory prior bevacizumab exposure, ...
Researchers have uncovered an early survival response in ovarian cancer cells that may limit the effectiveness of widely used ...
Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...
The approval is based on the results of Corcept’s Phase 3 ROSELLA trial, which showed improvements in both progression-free survival and overall survival. ・The approval covers adults with ...
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to ...
FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to 3 prior systemic regimens.
Preview this article 1 min In ovarian cancer alone — the fifth-most common cause of death in women — Lifyorli could ring up ...
The FDA has approved relacorilant (Lifyorli) in combination with nab-paclitaxel for the treatment of patients with ...
Understand the signs of premature ovarian failure and POI. Learn how to manage symptoms and protect your long-term health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results